Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion - Biomea Fusion (NASDAQ:BMEA)

Shares of Biomea Fusion Inc (NASDAQ:BMEA) are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.

Here’s what investors need to know.

Biomea Fusion shares are powering higher. What’s behind BMEA gains?

COVALENT-211 Reaches Full Enrollment With Topline Data Expected In Q1 2027

The clinical-stage biopharmaceutical firm announced that it has completed patient enrollment for COVALENT-211, its randomized, double-blind, placebo-controlled Phase II trial evaluating its oral menin inhibitor, icovamenib.